Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

Journal of Experimental and Clinical Cancer Research

Volumn 34, Issue 1, 2015, Pages

  Ferrari, Francesca ^a   Bellone, Stefania ^a   Black, Jonathan ^a   Schwab, Carlton L ^a   Lopez, Salvatore ^a   Cocco, Emiliano ^a   Bonazzoli, Elena ^a   Predolini, Federica ^a   Menderes, Gulden ^a   Litkouhi, Babak ^a   Ratner, Elena ^a   Silasi, Dan Arin ^a   Azodi, Masoud ^a   Schwartz, Peter E ^a   Santin, Alessandro D ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Bispecific antibody; CD3; EpCAM; Ovarian carcinosarcoma; T lymphocyte; Uterine carcinosarcoma

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; SOLITOMAB; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD3 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; EPCAM PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL COUNT; CELL VIABILITY; CHROMIUM RELEASE ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; UTERUS CARCINOMA; AGED; ANTAGONISTS AND INHIBITORS; CARCINOSARCOMA; CELL PROLIFERATION; COCULTURE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR CELL LINE; UTERINE NEOPLASMS;

AGED; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOSARCOMA; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELL ADHESION MOLECULE; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MIDDLE AGED; OVARIAN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; UTERINE NEOPLASMS;

EID: 84944326180     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-015-0241-7     Document Type: Article

References (26)

1. Schipf A, Mayr D, Kirchner T, Diebold J. Molecular genetic aberrations of ovarian and uterine carcinosarcomas - a cgh and fish study. Virchows Arch. 2008;452:259-68.
2. Cantrell LA, Van Le L. Carcinosarcoma of the ovary a review. Obstet Gynecol Surv. 2009;64:673-80. quiz 697.
3. Garg G, Shah JP, Kumar S, Bryant CS, Munkarah A, Morris RT. Ovarian and uterine carcinosarcomas: A comparative analysis of prognostic variables and survival outcomes. Int J Gynecol Cancer. 2010;20:888-94.
4. Choijamts B, Jimi S, Kondo T, Naganuma Y, Matsumoto T, Kuroki M, et al. Cd133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed mullerian tumor). Stem cells. 2011;29:1485-95.
5. Pietzner K, Woopen H, Richter R, Joens T, Braicu EI, Dimitrova D, et al. Expression of epithelial cell adhesion molecule in paired tumor samples of patients with primary and recurrent serous ovarian cancer. Int J Gynecol Cancer. 2013;23:797-802.
6. Munz M, Baeuerle PA, Gires O. The emerging role of epcam in cancer and stem cell signaling. Cancer Res. 2009;69:5627-9.
7. Armstrong A, Eck SL. Epcam: A new therapeutic target for an old cancer antigen. Cancer Biol Ther. 2003;2:320-6.
8. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, et al. Mt110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006;43:1129-43.
9. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, et al. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: Implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer. 2009;19:860-6.
10. English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, et al. Solitomab, an epithelial cell adhesion molecule/cd3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer. 2015;121:403-12.
11. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl). 1999;77:699-712.
12. Spurr NK, Durbin H, Sheer D, Parkar M, Bobrow L, Bodmer WF. Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI. Int J Cancer. 1986;38:631-6.
13. McLaughlin PM, Harmsen MC, Dokter WH, Kroesen BJ, van der Molen H, Brinker MG, et al. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res. 2001;61:4105-11.
14. Richter CE, Cocco E, Bellone S, Silasi DA, Rüttinger D, Azodi M, et al. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Am J Obstet Gynecol. 2010;203:582. e1-7.
15. Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, et al. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res. 2011;10:30-106.
16. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, et al. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res. 2005;65:2882-9.
17. Bellone S, Roque D, Cocco E, Gasparrini S, Bortolomai I, Buza N, et al. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. Br J Cancer. 2012;106:1543-50.
18. Radoja S, Saio M, Schaer D, Koneru M, Vukmanovic S, Frey AB. CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J Immunol. 2001;167:5042-51.
19. Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, et al. Antitumor vaccination: where we stand. Haematologica. 2000;85:1172-206.
20. Costello RT, Gastaut JA, Olive D. Tumor escape from immune surveillance. Arch Immunol Ther Exp (Warsz). 1999;47:83-8.
21. Sinkovics JG, Horvath JC. Vaccination against human cancers. Int J Oncol. 2000;16:81-96.
22. Walter M, Fiedler MW, Maxim Kebenko, Marie-Elisabeth Goebeler, et al. A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. Oral Abstract Session, Developmental Therapeutics - Clinical Pharmacology and Immunotherapy Oral Abstract Session 2012 ASCO Annual Meeting.
23. Burges A, Wimberger P, Kumper C, Gorbounova V, Sommer H, Schmalfeldt B, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res. 2007;13:3899-905.
24. Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134-40.
25. Sanford M. Blinatumomab: first global approval. Drugs. 2015;75:321-7.
26. Oak E, Bartlett NL. Blinatumomab for the treatment of B-cell lymphoma. Expert Opin Investig Drugs. 2015;24:715-24.